Fig. 4

Transcriptomic analysis during cancer evolution. A The horizontal bar plots of evolution path analysis (left) and clonal selection analysis (right) with mutation features. “metastasis” versus “primary” (LC: Metastasis panel) and “progression disease (PD),” “partial response (PR),” and “stable disease” (SD) in lung cancer (LC: drug response panel). “good response” and “poor response” in CML sampled at diagnosis (CML: drug response panel). Only the top 5 cancer signatures and top 5 metabolisms for “metastasis,” “PD,” and “poor response” with q value <  = 0.1 were shown. All the results are shown in Fig. S6. The bar indicates the mean Spearman correlation coefficient from each group. The standard error is shown as an error bar. Terms in red are cancer related and terms in black are metabolism related. B Fraction of significant features from “metastasis,” “PD,” or “poor response” that were verified by literature search